优化基于补体激活抗体的癌症免疫疗法：一种可行的策略？
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
作者信息
Fonsatti Ester, Di Giacomo Anna Maria, Maio Michele
机构信息
Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I,R,C,C,S, 33081 Aviano, Italy.
出版信息
J Transl Med. 2004 Jun 25;2(1):21. doi: 10.1186/1479-5876-2-21.
Passive immunotherapy with monoclonal antibodies (mAb) targeted to specific tumor-associated antigens is amongst the most rapidly expanding approaches to biological therapy of cancer. However, until now a limited number of therapeutic mAb has demonstrated clinical efficacy in selected neoplasia. Results emerging from basic research point to a deeper characterization of specific biological features of neoplastic cells as crucial to optimize the clinical potential of therapeutic mAb, and to identify cancer patients who represent the best candidates to antibody-based immunotherapy. Focus on the tissue distribution and on the functional role of membrane complement-regulatory proteins such as Protectin (CD59), which under physiologic conditions protects tissues from Complement (C)-damage, might help to optimize the efficacy of immunotherapeutic strategies based on C-activating mAb.
针对特定肿瘤相关抗原的单克隆抗体（mAb）被动免疫疗法是癌症生物治疗中发展最为迅速的方法之一。然而，到目前为止，仅有有限数量的治疗性单克隆抗体在特定肿瘤中显示出临床疗效。基础研究的结果表明，深入了解肿瘤细胞的特定生物学特征对于优化治疗性单克隆抗体的临床潜力以及识别最适合基于抗体的免疫治疗的癌症患者至关重要。关注膜补体调节蛋白如保护素（CD59）的组织分布和功能作用，在生理条件下保护组织免受补体（C）损伤，这可能有助于优化基于补体激活单克隆抗体的免疫治疗策略的疗效。
Zotero 插件